Olema Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for breast cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as Olema Pharmaceuticals, Inc. and changed its name to Olema Oncology, Inc. in November 2026. Olema Oncology, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.…
Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
Olema Oncology (NASDAQ: OLMA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 131 employees.
The shares were at 7.020 USD on 20 November 2026, down 14.3% over 52 weeks. Its 52-week range is 6.235 USD to 36.26 USD: the price is 80.6% below the high and 12.6% above the low.
Its market capitalisation is 615.00M USD.
Olema Oncology reports return on equity of -33.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 410.42M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 15 March 2027.